The Efficacy of Ferumoxytol for Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials.
INTRODUCTION
This systematic review and meta-analysis aims to explore the influence of ferumoxytol versus placebo on iron deficiency anemia.


METHODS
We search for randomized controlled trials (RCTs) assessing the effect of ferumoxytol on iron deficiency anemia on PubMed, EMbase, Web of science, EBSCO, and Cochrane library databases. This meta-analysis is performed using the random-effects model.


RESULTS
Four RCTs are included in the meta-analysis. Compared with the control group for iron deficiency anemia, intravenous ferumoxytol can significantly improve the proportion of patients with a ≥20 g/L hemoglobin (Hb) increase (RR = 18.43; 95% CI = 7.29-46.57; p < 0.00001), the proportion of patients with an Hb level ≥120 g/L (RR = 18.55; 95% CI = 8.66-39.72; p < 0.00001), transferrin saturation (mean difference = 11.08; 95% CI = 9.86-12.31; p < 0.00001) and FACIT-fatigue score (mean difference = 4.60; 95% CI = 3.21-6.00; p < 0.00001), but has no remarkable influence on adverse events (RR = 1.33; 95% CI = 0.84-2.10; p = 0.22), serious adverse events (RR = 1.22; 95% CI = 0.74-2.02; p = 0.44), and death (RR = 0.32; 95% CI = 0.05-1.95; p = 0.22).


CONCLUSIONS
Intravenous ferumoxytol can provide the important benefits for iron deficiency anemia.
['Shao|Yanping|Y|', 'Luo|Wenda|W|', 'Xu|Haiyan|H|', 'Zhang|Li|L|', 'Guo|Qunyi|Q|']
D018798:Anemia, Iron-Deficiency D052203:Ferrosoferric Oxide D006454:Hemoglobins D006801:Humans D016032:Randomized Controlled Trials as Topic
Ferumoxytol Iron deficiency anemia Meta-analysis Randomized controlled trials Hemoglobin level